Health
Experimental Alzheimer’s Drug Shows Promise in Reducing Dementia Risk
A new experimental treatment targeting amyloid plaques in the brain has shown promising early results in reducing the risk of Alzheimer’s-related dementia among asymptomatic patients. The drug, gantenerumab, was studied in a small group of individuals genetically predisposed to the neurodegenerative disease.
Researchers tracked 22 patients with genetic mutations that cause an overproduction of amyloid, a protein that clumps together to form plaques in the brain, a hallmark of Alzheimer’s disease. According to findings published in Lancet Neurology, participants who took gantenerumab for eight years saw their risk of developing symptoms drop from 100% to approximately 50%.
Long-Term Treatment May Be Key
The study’s lead author, Randall Bateman, a professor of neurology at Washington University School of Medicine in the U.S., emphasized the significance of the results. “Everyone in this study was destined to develop Alzheimer’s disease, and some of them haven’t yet,” Bateman said. “To give them the best opportunity to stay cognitively normal, we have continued treatment with another anti-amyloid antibody in hopes they will never develop symptoms at all.”
Notably, cognitive benefits were observed only in patients who received the treatment for the full eight years. Those who were treated for only two to three years did not show noticeable improvements, suggesting that long-term preventive therapy may be necessary for effectiveness.
Challenges and Limitations
Despite the encouraging results, experts have pointed out limitations in the study. Charles Marshall, a professor of clinical neurology at Queen Mary University of London, called the findings “very exciting” but noted that the study involved a small number of participants and was a secondary evaluation rather than a primary clinical trial.
Another concern is that gantenerumab is not as effective as some newer amyloid-reducing treatments, suggesting there may be even better options available. The drug was discontinued in 2022 after failing to slow symptoms in a trial involving over 1,900 participants with more common forms of Alzheimer’s disease.
Future Research Needed
While gantenerumab has shown potential in genetically predisposed individuals, further research is required to determine the optimal treatment duration, the effects on non-genetic cases of Alzheimer’s, and possible side effects. Some anti-amyloid drugs have been linked to brain abnormalities and localized swelling, though most side effects resolve on their own. In the study, two participants had to stop taking the drug due to side effects, but no life-threatening adverse effects were reported.
The findings contribute to the growing body of research on anti-amyloid therapies, highlighting the need for continued investigation into more effective Alzheimer’s prevention and treatment strategies.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
